Details for Patent: 7,994,364

Which drugs does patent 7,994,364 protect, and when does it expire?

Patent 7,994,364 protects NUCYNTA and NUCYNTA ER and is included in three NDAs.

This patent has forty-five patent family members in twenty-six countries.

Summary for Patent: 7,994,364

Title:	Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Abstract:	A hitherto unknown crystalline form of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.
Inventor(s):	Fischer; Andreas (Huertgenwald, DE), Buschmann; Helmut (Esplugues de Llobregat, ES), Gruss; Michael (Aachen, DE), Lischke; Dagmar (Eschweiler, DE)
Assignee:	Gruenenthal GmbH (Aachen, DE)
Application Number:	12/634,777
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,994,364
Patent Claim Types: see list of patent claims	Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,994,364

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	SOLUTION;ORAL	203794-001	Oct 15, 2012		DISCN	Yes	No			Y	Y		MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-001	Aug 25, 2011		RX	Yes	No			Y	Y		MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-001	Aug 25, 2011		RX	Yes	No			Y	Y		RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-002	Aug 25, 2011		RX	Yes	No			Y	Y		RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-002	Aug 25, 2011		RX	Yes	No			Y	Y		MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-003	Aug 25, 2011		RX	Yes	No			Y	Y		MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-003	Aug 25, 2011		RX	Yes	No			Y	Y		RELIEF OF MODERATE TO SEVERE CHRONIC PAIN

Foreign Priority and PCT Information for Patent: 7,994,364

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	04015091	Jun 28, 2004

International Family Members for US Patent 7,994,364

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	049949
Argentina	116052
Austria	E368639
Austria	E496021
Australia	2005256512
Brazil	122018014454
Brazil	PI0512792